Kyle Lapham

Kyle Lapham is the Chief Executive Officer (CEO) of resistanceBio, a biotechnology company.12 He is a seasoned biotech executive and technology/operations leader with extensive experience in the industry.1

Career Highlights

Startup Experience:: Kyle is a three-time startup veteran, having held leadership positions in multiple biotech companies.1

Previous Roles::

• Chief Technology Officer at PACT Pharma (April 2020 - March 2022)
• Chief Technology Officer at Synthego Corporation (August 2017 - January 2020)
• Vice President of Automation at Counsyl (April 2015 - August 2017)

Expertise

Kyle specializes in:

• Increasing access to cutting-edge science through automation
• Organizational alignment
• World-class technical operations
• Helping biotech and pharma startups transition from research to commercialization

His experience spans over 15 years in technology and operations leadership.1

Education

Kyle holds a degree in Genetics and Molecular Biology from UC Davis, which he attended from 2001 to 2005.1

Current Role

As CEO of resistanceBio, Kyle has been instrumental in the company's recent developments:

• He played a key role in securing a recent investment for the company
• resistanceBio has filed a notice of an exempt offering of securities to raise $12,776,288.00 in new equity and debt financing2

Kyle Lapham's LinkedIn profile (username: kylelapham) provides a comprehensive overview of his professional experience and achievements in the biotechnology sector.1